KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 6,669 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $11.97, for a total value of $79,827.93. Following the transaction, the chief executive officer now directly owns 287,811 shares in the company, valued at approximately $3,445,097.67. The trade was a 2.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
KalVista Pharmaceuticals Stock Up 0.6 %
Shares of KalVista Pharmaceuticals stock traded up $0.07 during midday trading on Monday, hitting $11.99. The company's stock had a trading volume of 597,319 shares, compared to its average volume of 419,120. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50. The firm has a market capitalization of $592.52 million, a P/E ratio of -3.29 and a beta of 0.76. The stock has a 50-day simple moving average of $9.38 and a 200-day simple moving average of $10.28.
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last announced its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.01. As a group, sell-side analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.
Analyst Ratings Changes
A number of research analysts recently issued reports on KALV shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. TD Cowen assumed coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $30.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $23.80.
Read Our Latest Research Report on KALV
Institutional Trading of KalVista Pharmaceuticals
Hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC boosted its holdings in shares of KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after purchasing an additional 1,319 shares during the period. HighVista Strategies LLC boosted its holdings in shares of KalVista Pharmaceuticals by 4.5% during the third quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company's stock worth $386,000 after purchasing an additional 1,432 shares during the period. Legal & General Group Plc boosted its holdings in shares of KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after purchasing an additional 1,494 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of KalVista Pharmaceuticals by 8.0% during the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company's stock worth $262,000 after purchasing an additional 1,670 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock worth $87,000 after purchasing an additional 2,043 shares during the period.
About KalVista Pharmaceuticals
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
